{"id":"doc001","title":"EGFR Signaling in Lung Cancer","text":"EGFR (Epidermal Growth Factor Receptor) is a key oncogenic driver in non-small cell lung cancer. Its activation leads to uncontrolled cell proliferation. EGFR inhibitors such as gefitinib and erlotinib have shown positive response in patients with EGFR mutations.","doi":"10.1000/example1"}
{"id":"doc002","title":"Role of IL-6 in Inflammatory Pathways","text":"IL-6 is a major pro-inflammatory cytokine that activates the JAK/STAT3 signaling pathway. Chronic upregulation of IL-6 is associated with autoimmune diseases and several cancers. Targeting IL-6 or JAK-STAT pathway may reduce inflammation and tumor progression.","doi":"10.1000/example2"}
{"id":"doc003","title":"Kinase Inhibitors in Oncology","text":"Small molecule kinase inhibitors block abnormal signaling pathways involved in cancer. Selective inhibition of cancer-specific kinases leads to reduced toxicity and improved therapeutic outcome. Combination therapy with kinase inhibitors increases overall survival rates.","doi":"10.1000/example3"}
{"id":"doc004","title":"TNF-alpha and Cell Survival","text":"TNF-alpha regulates apoptosis through NF-kB signaling. Overexpression of TNF-alpha contributes to inflammatory diseases. Blocking TNF-alpha using monoclonal antibodies reduces inflammation.","doi":"10.1000/example4"}
{"id":"doc005","title":"VEGF in Tumor Angiogenesis","text":"VEGF (Vascular Endothelial Growth Factor) promotes blood vessel formation. Tumors overexpress VEGF to increase nutrient supply. Anti-VEGF drugs such as bevacizumab inhibit angiogenesis and restrict tumor growth.","doi":"10.1000/example5"}
{"id":"doc006","title":"PI3K/AKT Pathway in Cancer Progression","text":"The PI3K/AKT pathway regulates cell growth, survival, and metabolism. Mutations or amplification of PI3K and loss of PTEN lead to hyperactivation, contributing to tumor growth and therapy resistance.","doi":"10.1000/example6"}
{"id":"doc007","title":"p53 Tumor Suppressor Mechanisms","text":"p53 controls DNA repair, apoptosis, and cell cycle arrest. Mutations in TP53 are found in over 50% of cancers. Restoring p53 activity is a promising therapeutic direction.","doi":"10.1000/example7"}
{"id":"doc008","title":"MAPK/ERK Signaling Cascade","text":"The MAPK/ERK pathway is activated by growth factors and regulates proliferation. KRAS and BRAF mutations hyperactivate this cascade in melanoma and colon cancers.","doi":"10.1000/example8"}
{"id":"doc009","title":"Apoptosis and BCL-2 Family Proteins","text":"BCL-2 proteins regulate intrinsic apoptosis. Overexpression of anti-apoptotic BCL-2 enables cancer cell survival. BCL-2 inhibitors like venetoclax are used in leukemia.","doi":"10.1000/example9"}
{"id":"doc010","title":"Immune Checkpoint Inhibition","text":"PD-1/PD-L1 interaction suppresses T-cell activation. Checkpoint inhibitors such as nivolumab and pembrolizumab block this interaction, restoring anti-tumor immunity.","doi":"10.1000/example10"}
{"id":"doc011","title":"BRCA1/2 and DNA Repair","text":"BRCA1/2 genes regulate homologous recombination DNA repair. Their loss sensitizes tumors to PARP inhibitors through synthetic lethality.","doi":"10.1000/example11"}
{"id":"doc012","title":"Oxidative Stress and NRF2 Pathway","text":"NRF2 mediates antioxidant response. Tumors exploit NRF2 hyperactivation to survive oxidative stress, making it a dual-role target.","doi":"10.1000/example12"}
{"id":"doc013","title":"mTOR Signaling and Autophagy","text":"mTOR suppresses autophagy. Inhibitors like rapamycin induce autophagy and can slow tumor growth, especially in metabolic cancers.","doi":"10.1000/example13"}
{"id":"doc014","title":"WNT/β-Catenin Pathway in Tumorigenesis","text":"The WNT/β-catenin signaling pathway is essential for embryonic development but becomes oncogenic when dysregulated. Stabilized β-catenin translocates to the nucleus and activates genes driving cell proliferation and stemness.","doi":"10.1000/example14"}
{"id":"doc015","title":"HIF-1α and Tumor Hypoxia Adaptation","text":"HIF-1α is stabilized under low oxygen and regulates angiogenesis, metabolism, and survival. Tumors exploit HIF signaling to adapt to hypoxic microenvironments and resist therapies.","doi":"10.1000/example15"}
{"id":"doc016","title":"NF-κB Signaling in Chronic Inflammation","text":"NF-κB drives transcription of inflammatory cytokines, survival genes, and stress responses. Constitutive activation in tumors promotes growth, immune evasion, and therapy resistance.","doi":"10.1000/example16"}
{"id":"doc017","title":"JAK/STAT Pathway Dysregulation in Leukemia","text":"Aberrant JAK/STAT activation through mutations or cytokine loops drives leukemic stem cell survival. JAK inhibitors show benefit in myeloproliferative disorders.","doi":"10.1000/example17"}
{"id":"doc018","title":"Cell Cycle Regulation by Cyclins and CDKs","text":"Cyclin–CDK complexes control cell cycle transitions. Overexpression of Cyclin D/E or loss of CDK inhibitors leads to uncontrolled proliferation. CDK4/6 inhibitors are effective in breast cancer therapy.","doi":"10.1000/example18"}
{"id":"doc019","title":"Epigenetic Regulation via DNA Methylation","text":"DNA methyltransferases silence tumor suppressor genes. Demethylation therapies restore gene expression and improve responsiveness to immune therapies.","doi":"10.1000/example19"}
{"id":"doc020","title":"Autophagy in Cancer Metabolism","text":"Cancer cells use autophagy to recycle nutrients and survive metabolic stress. Dual targeting of metabolism + autophagy enhances therapeutic efficacy in nutrient-poor tumors.","doi":"10.1000/example20"}
